Overexpression of romo1 is an unfavorable prognostic biomarker and a predictor of lymphatic metastasis in non-small cell lung cancer patients

Hong Jun Kim, Min Jee Jo, Bo Ram Kim, Jung Lim Kim, Yoon A. Jeong, Yoo Jin Na, Seong Hye Park, Suk Young Lee, Dae Hee Lee, Baek-Hui Kim, Young Do Yoo, Sang Cheul Oh

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Introduction: Reactive oxygen species modulator-1 (Romo1) is a protein that modulates levels of reactive oxygen species (ROS) and has been reported to affect cancer cell invasion and proliferation via persistent inflammation. Several studies have demonstrated the clinical application of Romo1 as a prognostic marker in non-small cell lung cancer (NSCLC); however, there have been no studies investigating the mechanism by which Romo1 adversely affects the prognosis of these patients. Methods: We examined Romo1, ROS, and vascular endothelial growth factor (VEGF) in tumor tissues immunohistochemically. We conducted survival analyses of patients who had curative resection (n=30) in accordance with clinical parameters including levels of Romo1 expression. Results: Romo1 levels were associated with serologic inflammatory markers and high lymphatic metastatic tendencies. Significantly longer disease-free survival (68.7 vs 24.2 months, P=0.031) and overall survival (92.7 vs 51.6 months) were observed in the group with low Romo1 compared with high Romo1. Survival outcomes were also significantly associated with serologic inflammatory markers. Spearman’s correlation analyses demonstrated significant positive correlations of Romo1 expression with VEGF-C (P=0.008, R=0.478) and ROS (P=0.016, R=0.436) in tumor samples. Conclusion: The current study demonstrates that Romo1 induces lymphatic metastasis of NSCLC by modulating persistent inflammation and oxidative stress (ROS)/VEGF signaling. Lymphatic metastasis associated with elevated Romo1 was shown to be a key reason for unfavorable survival rates.

Original languageEnglish
Pages (from-to)4233-4246
Number of pages14
JournalOncoTargets and Therapy
Volume11
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

Lymphatic Metastasis
Non-Small Cell Lung Carcinoma
Reactive Oxygen Species
Biomarkers
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor C
Inflammation
Neoplasms
Survival
Survival Analysis

Keywords

  • Inflammation
  • Non-Small cell lung carcinoma
  • Reactive oxygen species
  • Reactive oxygen species modulator-1
  • Vascular endothelial growth factor A

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Overexpression of romo1 is an unfavorable prognostic biomarker and a predictor of lymphatic metastasis in non-small cell lung cancer patients. / Kim, Hong Jun; Jo, Min Jee; Kim, Bo Ram; Kim, Jung Lim; Jeong, Yoon A.; Na, Yoo Jin; Park, Seong Hye; Lee, Suk Young; Lee, Dae Hee; Kim, Baek-Hui; Yoo, Young Do; Oh, Sang Cheul.

In: OncoTargets and Therapy, Vol. 11, 01.01.2018, p. 4233-4246.

Research output: Contribution to journalArticle

Kim, Hong Jun ; Jo, Min Jee ; Kim, Bo Ram ; Kim, Jung Lim ; Jeong, Yoon A. ; Na, Yoo Jin ; Park, Seong Hye ; Lee, Suk Young ; Lee, Dae Hee ; Kim, Baek-Hui ; Yoo, Young Do ; Oh, Sang Cheul. / Overexpression of romo1 is an unfavorable prognostic biomarker and a predictor of lymphatic metastasis in non-small cell lung cancer patients. In: OncoTargets and Therapy. 2018 ; Vol. 11. pp. 4233-4246.
@article{d63554d9ba944b2aa421f72b75159c5f,
title = "Overexpression of romo1 is an unfavorable prognostic biomarker and a predictor of lymphatic metastasis in non-small cell lung cancer patients",
abstract = "Introduction: Reactive oxygen species modulator-1 (Romo1) is a protein that modulates levels of reactive oxygen species (ROS) and has been reported to affect cancer cell invasion and proliferation via persistent inflammation. Several studies have demonstrated the clinical application of Romo1 as a prognostic marker in non-small cell lung cancer (NSCLC); however, there have been no studies investigating the mechanism by which Romo1 adversely affects the prognosis of these patients. Methods: We examined Romo1, ROS, and vascular endothelial growth factor (VEGF) in tumor tissues immunohistochemically. We conducted survival analyses of patients who had curative resection (n=30) in accordance with clinical parameters including levels of Romo1 expression. Results: Romo1 levels were associated with serologic inflammatory markers and high lymphatic metastatic tendencies. Significantly longer disease-free survival (68.7 vs 24.2 months, P=0.031) and overall survival (92.7 vs 51.6 months) were observed in the group with low Romo1 compared with high Romo1. Survival outcomes were also significantly associated with serologic inflammatory markers. Spearman’s correlation analyses demonstrated significant positive correlations of Romo1 expression with VEGF-C (P=0.008, R=0.478) and ROS (P=0.016, R=0.436) in tumor samples. Conclusion: The current study demonstrates that Romo1 induces lymphatic metastasis of NSCLC by modulating persistent inflammation and oxidative stress (ROS)/VEGF signaling. Lymphatic metastasis associated with elevated Romo1 was shown to be a key reason for unfavorable survival rates.",
keywords = "Inflammation, Non-Small cell lung carcinoma, Reactive oxygen species, Reactive oxygen species modulator-1, Vascular endothelial growth factor A",
author = "Kim, {Hong Jun} and Jo, {Min Jee} and Kim, {Bo Ram} and Kim, {Jung Lim} and Jeong, {Yoon A.} and Na, {Yoo Jin} and Park, {Seong Hye} and Lee, {Suk Young} and Lee, {Dae Hee} and Baek-Hui Kim and Yoo, {Young Do} and Oh, {Sang Cheul}",
year = "2018",
month = "1",
day = "1",
doi = "10.2147/OTT.S161587",
language = "English",
volume = "11",
pages = "4233--4246",
journal = "OncoTargets and Therapy",
issn = "1178-6930",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Overexpression of romo1 is an unfavorable prognostic biomarker and a predictor of lymphatic metastasis in non-small cell lung cancer patients

AU - Kim, Hong Jun

AU - Jo, Min Jee

AU - Kim, Bo Ram

AU - Kim, Jung Lim

AU - Jeong, Yoon A.

AU - Na, Yoo Jin

AU - Park, Seong Hye

AU - Lee, Suk Young

AU - Lee, Dae Hee

AU - Kim, Baek-Hui

AU - Yoo, Young Do

AU - Oh, Sang Cheul

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Introduction: Reactive oxygen species modulator-1 (Romo1) is a protein that modulates levels of reactive oxygen species (ROS) and has been reported to affect cancer cell invasion and proliferation via persistent inflammation. Several studies have demonstrated the clinical application of Romo1 as a prognostic marker in non-small cell lung cancer (NSCLC); however, there have been no studies investigating the mechanism by which Romo1 adversely affects the prognosis of these patients. Methods: We examined Romo1, ROS, and vascular endothelial growth factor (VEGF) in tumor tissues immunohistochemically. We conducted survival analyses of patients who had curative resection (n=30) in accordance with clinical parameters including levels of Romo1 expression. Results: Romo1 levels were associated with serologic inflammatory markers and high lymphatic metastatic tendencies. Significantly longer disease-free survival (68.7 vs 24.2 months, P=0.031) and overall survival (92.7 vs 51.6 months) were observed in the group with low Romo1 compared with high Romo1. Survival outcomes were also significantly associated with serologic inflammatory markers. Spearman’s correlation analyses demonstrated significant positive correlations of Romo1 expression with VEGF-C (P=0.008, R=0.478) and ROS (P=0.016, R=0.436) in tumor samples. Conclusion: The current study demonstrates that Romo1 induces lymphatic metastasis of NSCLC by modulating persistent inflammation and oxidative stress (ROS)/VEGF signaling. Lymphatic metastasis associated with elevated Romo1 was shown to be a key reason for unfavorable survival rates.

AB - Introduction: Reactive oxygen species modulator-1 (Romo1) is a protein that modulates levels of reactive oxygen species (ROS) and has been reported to affect cancer cell invasion and proliferation via persistent inflammation. Several studies have demonstrated the clinical application of Romo1 as a prognostic marker in non-small cell lung cancer (NSCLC); however, there have been no studies investigating the mechanism by which Romo1 adversely affects the prognosis of these patients. Methods: We examined Romo1, ROS, and vascular endothelial growth factor (VEGF) in tumor tissues immunohistochemically. We conducted survival analyses of patients who had curative resection (n=30) in accordance with clinical parameters including levels of Romo1 expression. Results: Romo1 levels were associated with serologic inflammatory markers and high lymphatic metastatic tendencies. Significantly longer disease-free survival (68.7 vs 24.2 months, P=0.031) and overall survival (92.7 vs 51.6 months) were observed in the group with low Romo1 compared with high Romo1. Survival outcomes were also significantly associated with serologic inflammatory markers. Spearman’s correlation analyses demonstrated significant positive correlations of Romo1 expression with VEGF-C (P=0.008, R=0.478) and ROS (P=0.016, R=0.436) in tumor samples. Conclusion: The current study demonstrates that Romo1 induces lymphatic metastasis of NSCLC by modulating persistent inflammation and oxidative stress (ROS)/VEGF signaling. Lymphatic metastasis associated with elevated Romo1 was shown to be a key reason for unfavorable survival rates.

KW - Inflammation

KW - Non-Small cell lung carcinoma

KW - Reactive oxygen species

KW - Reactive oxygen species modulator-1

KW - Vascular endothelial growth factor A

UR - http://www.scopus.com/inward/record.url?scp=85057739605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057739605&partnerID=8YFLogxK

U2 - 10.2147/OTT.S161587

DO - 10.2147/OTT.S161587

M3 - Article

AN - SCOPUS:85057739605

VL - 11

SP - 4233

EP - 4246

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

SN - 1178-6930

ER -